Literature DB >> 2404216

How frequently does classic amyotrophic lateral sclerosis develop in survivors of poliomyelitis?

C Armon1, J R Daube, A J Windebank, L T Kurland.   

Abstract

There is a paucity of reports of classic amyotrophic lateral sclerosis (ALS) developing in survivors of paralytic poliomyelitis. We describe a patient with classic ALS and an antecedent paralytic disease thought to have been poliomyelitis from which she recovered completely. If the paucity of ALS preceded by true poliomyelitis is not merely a matter of underreporting, antecedent paralytic poliomyelitis may have a protective role against the development of ALS. This has implications relevant to pathogenesis and to projected secular trends of ALS incidence since the introduction of poliomyelitis vaccines. There is a need to establish the incidence of cases of classic ALS in patients with antecedent poliomyelitis.

Entities:  

Mesh:

Year:  1990        PMID: 2404216     DOI: 10.1212/wnl.40.1.172

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Poliomyelitis.

Authors:  D Kidd; A J Williams; R S Howard
Journal:  Postgrad Med J       Date:  1996-11       Impact factor: 2.401

2.  Multiple sclerosis presenting as late functional deterioration after poliomyelitis.

Authors:  E Chroni; R S Howard; C P Panayiotopoulos; G T Spencer
Journal:  Postgrad Med J       Date:  1995-01       Impact factor: 2.401

3.  Lightning can strike twice: an unlucky patient of neurological interest.

Authors:  Ebony S Gilbee
Journal:  BMJ Case Rep       Date:  2013-06-24

4.  Comparative study of spinal cord ubiquitin expression in post-poliomyelitis and sporadic amyotrophic lateral sclerosis.

Authors:  H Ito; A Hirano
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

5.  Motor neuron disease and past poliomyelitis. Geographic study in Hokkaido, the northern-most island of Japan. ALS Study Group.

Authors:  F Moriwaka; H Okumura; K Tashiro; T Hamada; A Matsumoto; H Matsumoto; N Itoh; R Shindo; N Takahata
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.